Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1026706 in Healthy Chinese and Japanese Volunteers
NCT02652416Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 1026706 in diabetic macular edema (DME) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Subjects With Drug-related Adverse Events up to 19 days. Started Sep 2016; status: completed.
02
Drugs
BI 1026706
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02652416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652416.